There is strong evidence implicating human papillomavirus type 16 (HPV16) in the genesis of human genital cancer. Viral DNA has been identified in invasive carcinoma of the uterine cervix and in cell lines derived from cervical carcinomas. These sequences are actively transcribed, and translation products corresponding to the early (E)-region genes have been identffied. The most abundant viral protein is the E7 protein, which has been shown to possess transforming activit for both established and primary cells. In addition, it has been shown to bind to a cellular tumor suppressor, the retinoblastoma gene product . In view of these properties, we have undertaken the immunological analysis of this protein and have identified four T-cell epitopes and three B-cell epitopes by using a series of overlapping peptides spanning the entire HPV16 E7 sequence. Two of the B-cell epitopes were recognized by antisera from mice with three different murine (H-2) haplotypes (k, d, and s) immunized with two different E7 fusion proteins and from Fischer rats seeded with baby rat kidney cells transformed by HPV16 E7 and ras. A third B-cell epitope was recognized by antisera from CBA mice seeded with HPV16 E7-expressing L cells. Two regions of the protein contain common B-and T-cell epitopes, one of which appears to be particularly immunodominant.
Human papillomaviruses (HPVs) are a group of heterogeneous viruses, some of which infect anogenital epithelia and are implicated in the etiology of cervical cancer (41) . HPV DNA is present in the majority of premalignant and malignant cancers of the cervix, with HPV type 16 (HPV16) being the type most commonly identified in such lesions (9, 34, 35) . Integrated copies of viral DNA are found in invasive carcinomas, while nonintegrated (episomal) copies are found in premalignant lesions such as cervical intraepithelial neoplasia (10, 18) . Genetic analysis has shown that the E6 and E7 open reading frames (ORFs) of some papillomaviruses are necessary and sufficient for efficient cellular transformation. The E6 and E7 ORFs of HPV16 have been shown to possess transforming activity for mouse fibroblasts (62) and primary human keratinocytes (43, 48) . The E7 gene product can also cooperate with an activated ras oncogene to fully transform and immortalize primary rodent cells (33, 42, 56) , and its continued expression has been shown to be required for maintenance of this transformed phenotype (7) . The E6 and E7 ORF products also bind two cellular regulatory proteins: the cellular p53 protein (60) and the retinoblastoma gene product (pRb-105) (11) , respectively. Both of these proteins belong to a class of tumor suppressor proteins which appear to play an important role in suppressing the transformed phenotype (15, 22) . Finally, HPV16 E7 is the most abundant viral protein in CaSki and SiHa cells (51) which contain integrated copies of HPV16 DNA and in HPV16-containing cervical carcinoma biopsy tissue (54) .
It is clear from human and animal studies that papillomaviruses contribute significantly to the development of many carcinomas, but we still do not have a clear understanding of the importance of other interacting viral, chemical, or cellu-lar factors. The immunological approach to the prevention of HPV disease requires a thorough analysis of the viral proteins against which humoral and cellular immune responses are mounted during and after infection. At present, although there is little direct evidence for the efficacy of either humoral or cell-mediated immunity in the control of HPV infection, an important role for T-cell monitoring has been postulated because of the link between HPV disease and cellular immunodeficiency (16, 20, 27, 31, 37, 49, 55) . However, the nature of this response has yet to be defined.
The analysis of both human and experimental tumors for which there is a known (or strongly suspected) viral etiology indicates that T-cell surveillance mechanisms are centrally involved in limiting the emergence or effecting the regression of such tumors (2, 26, 30) . Recently, Chen et al. (3) showed that mice immunized with HPV16 E7-expressing nontumorigenic fibroblast cells were protected against a challenge with tumorigenic HPV16 E7-expressing melanoma cells. This protection was E7 specific and was mediated by class I-restricted CD8+ T lymphocytes. This is the first report of an HPV-encoded protein stimulating tumor rejection and stresses the importance of studying this protein in greater detail from an immunological point of view.
Anti-E7 antibodies have also been detected in the serum of approximately 20% of patients with HPV16-associated cervical lesions (17, 24) Mammalian expression vectors pJ4Q16E7, pJ5Q16E7, and pJ6f1l6E7 were generated by insertion of the 0.3-kb BamHIEcoRI HPV16 E7 fragment excised from pGEX16E7 into the plasmids pJ4Q, pJ5fl, and pJ6Ql under control of, respectively, the Moloney murine leukemia virus long terminal repeat (LTR), the mouse mammary tumor virus LTR, and the rat ,-actin promoter, which have previously been described (56) . The plasmid pTKpAT, containing the 3.4-kb herpes simplex virus tk gene and tk promoter, has also been previously described (36) . Transfection of murine L cells with HPV16 E7. LM(tk-) cells (61) were obtained from the American Type Culture Collection (ATCC CCL 1.3) and were maintained in Dulbecco's modified Eagle's medium (Flow Laboratories) supplemented with 10% fetal calf serum, 2 mM glutamine, 60 jig of penicillin per ml, and 100 ,ug of streptomycin per ml at 37°C and 5% CO2. DNA was introduced into the cells (0.5 x 106 to 1.0 x 106 cells per 10-cm dish) by the calcium phosphate precipitation method of Graham and van der Eb (19), using a molar ratio of E7 plasmid to tk plasmid of 10:1. At 24 to 36 h posttransfection, cells were split 1:4 and fed HAT (100 FtM hypoxanthine, 0.4 p.M aminopterin, 16 ,uM thymidine) (Sigma Chemicals, Poole, Dorset, United Kingdom) selective medium. HAT-resistant colonies were visible at 11 days posttransfection and were allowed to grow for a further 7 days before being passaged into 25-cm2 flasks for continued growth. Cells were then seeded into 96-well Costar dishes for cloning by limiting dilution. HAT selection medium was added 7 days after seeding, and wells containing single colonies were monitored and passaged into 25-cm2 flasks for further expansion.
High-molecular-weight DNA and poly(A)+ RNA were prepared from a number of J4I16E7 and J6Q16E7 HATresistant clones, LM(tk-) cells transfected with pTKpAT alone as a negative control, and SiHa cells used as a positive control for detection of HPV16 E7-specific DNA and RNA by polymerase chain reaction amplification (38, 46) (data not shown).
Transformation and immortalization of primary BRK cells by activated ras and HPV16 E7. Five-day-old primary baby rat kidney (BRK) cells (Fischer derived) were transfected with the plasmid pJ5fI16E7 and a plasmid expressing the 6.6-kb EJ-ras oncogene (52) at a molar ratio of 1:1 by using calcium phosphate precipitation. Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM glutamine, 60 ,ug of penicillin per ml, and 100 ,ug of streptomycin (Flow Laboratories) per ml at 37°C and 5% CO2. Dexamethasone (10-7 M) was included in the culture medium, resulting in the induced expression of HPV16 E7 under the control of the glucocorticoid regulatory element of the mouse mammary tumor virus LTR. These cells were fully transformed, and seeding of syngeneic Fischer rats with 2 x 106 E7-ras-transformed BRK cells resulted in the vigorous formation of tumors at the site of inoculation 10 days postimmunization (data not shown).
Peptides. Overlapping peptides spanning the entire HPV16 E7 protein were synthesized according to the method of Houghten (21) . Each peptide was 20 amino acids long and overlapped another peptide by 15 residues, with the exception of the last three, which were 19, 14, and 9 residues long, respectively (Fig. 1) . Two other peptides, one from the C terminus (TPTLHEYMLDLQPETTDLYC) and one from the N terminus (THVDIRTLEDLLMGTLGIVC) of E7, were also synthesized for immunization of rabbits and generation of anti-E7 antiserum. All peptides used were of greater than 90% purity.
Antibodies. Anti-E7 peptide antibodies were raised in rabbits by immunization with the two synthetic peptides described above coupled to T-cell proliferation assays. Single-cell suspensions were made of periaortic and inguinal lymph nodes removed from CBA mice 12 days postimmunization. Cells were pelleted, washed in PBS, and suspended in Click's extra-high-amino acid medium supplemented with 2 mM glutamine, 60 ,ug of penicillin per ml, 100 ,ug of streptomycin per ml, 5 x 10-6 M 2-mercaptoethanol, and 0.5% normal mouse serum at a density of 4 vested on an automatic cell harvester (Skatron, Tranby, Norway), and radioactivity was counted in a beta-counter (LKB, Betaplace, Sweden). Controls included cells stimulated with fusion proteins at 0.1 and 0.01 ,ug/ml or cells without antigen.
Amino acid sequence analysis and secondary-structure predictions. Secondary structure-predictions for the HPV16 E7 protein were made by using a suite of programs composed of a number of different algorithms from the literature which predict various aspects of protein secondary structure (Fig.  2) .
The traces WKS, WJANIN, WHPLC, and WPPI were used for the prediction of B-cell epitopes by assessing the accessibility and hydrophilicity of a protein. PRIFTA and FPPIA describe the computer prediction of amphipathic helices in order to identify T-cell antigenic sites.
The WKS trace (25) indicates the flexibility of the amino acid backbone of the protein according to whether a particular residue is surrounded by flexible or inflexible residues. An increase in the height of the trace indicates greater chain flexibility. WJANIN predicts the level of regional accessibility based on the partition coefficient of each amino acid between the surface and internal volumes of globular proteins (23) . WHPLC (40) and WFPPI (14) scales are derived from empirical determination of hydrophilicity of amino acids as determined from high-performance liquid chromatography retention data and the partitioning of residues between octanol and water, respectively. The height of the trace indicates greater hydrophilicity.
Instead of searching for extended regions of hydrophilicity or hydrophobicity (5, 32), FPPIA, FPPIB, and FPPIC search for the periodic occurrence of hydrophilic residues at 3.6, 2.1, and 3.0 residue intervals, respectively, to fit the model of an amphipathic helix. The height of the trace indicates the likelihood of an amphipathic helix forming from that region of the protein.
The CORE trace predicts the likelihood of regions of the amino acid sequence being in the core of the folded protein (6) . An upward spike in the trace indicates a noncore region; a downward spike indicates a core region. The deeper the splice, the more rules predict the residue to be in a core region.
ALPHA, BETA, and COIL constitute the Leeds secondary-structure prediction suite and indicate the likelihood of the occurrence of alpha helices, beta chains, and random coils, respectively (13) .
Epitope mapping. B-cell epitopes were identified by screening antisera from immunized animals against the nested set of overlapping E7 peptides by ELISA. T-cell epitopes were determined by stimulation of lymph node cells with fusion proteins, individual peptides (used at 10 ,ug/ml), and pools of three or four peptides (used at a combined concentration of 10 ,g/ml). Reactivities to clusters of neighboring peptides were noted, and the boundaries of epitopes were determined by analysis of common residues.
Peptides were considered positive in proliferation assays if the mean [3H]thymidine incorporation in triplicate wells was greater than 3 times the value for no-antigen wells for the GST16E7-immunized mice and 4.5 times the value for noantigen wells for protein A-E7-immunized mice.
RESULTS
T-cell epitopes. CBA (H-2k) mice were immunized with both the GST16E7 and protein A-E7 fusion proteins, and lymph node cells from the mice responded well to stimulation with both fusion proteins and peptides (Fig. 3) . The background no-antigen levels of thymidine incorporation were higher in the GST16E7-immunized mice (Fig. 3A) than in the protein A-E7-immunized mice (Fig. 3B) showed the greatest proliferation of all the pools in both GST16E7-and protein A-E7-immunized mice. The epitope most strongly recognized in all experiments with both GST16E7-and protein A-E7-immunized CBA mice was T2. The fact that only peptide 944 and no other neighboring peptides produced a stimulatory response meant that the limits of epitope T3 could not be more precisely determined because of the length of the peptides used in this study.
B-cell epitopes. Day 14 (Fig. 4A ) and day 28 (Fig. 4B ) antisera taken from BALB/c, B10.S, and CBA mice immunized with the GST16E7 fusion protein were assayed by ELISA with fusion proteins and peptides bound to wells as targets. Animals were not boosted in this experiment. In a second series of immunizations, using both GST16E7 (Fig.   5A ) and protein A-E7 fusion proteins (Fig. Sb) , antisera were taken on days 21 and 35 and similarly assayed. Both fusion proteins were recognized in ELISAs, as were the same clusters of overlapping peptides.
Two epitopes were defined on the basis of these results. Amino acid residues recognized were EYMLDLQPETT, designated epitope Bi (residues 10 to 20), and EEDEIDG PAGQAEPDR, designated B2 (residues 35 to 49), with epitope B2 being the most strongly recognized region in all three strains of mice. The suggestion of a third B-cell epitope was evident in antisera taken from CBA mice on day 28 postimmunization (Fig. 4B ) (residues 70 to 79; QSTHVD IRTL), although the reactivity with peptides containing these common residues was much weaker than for the other defined B-cell epitopes.
Antisera from CBA mice seeded with L cells transfected with HPV16 E7 showed a pattern of epitope recognition similar to that of mice immunized with fusion proteins, except for a much stronger recognition of epitope B3 (covered by peptides 945, 946, and 947) (Fig. 6) . In this case, epitope Bi appeared to be recognized as strongly as if not more strongly than epitope B2. Preliminary analysis of a large number of supernatants from hybridomas generated against the HPV16 E7 fusion proteins also suggests that epitope B3 is indeed recognized by murine antibodies raised against HPV16 E7, but the frequency of occurrence of B-cell precursors directed against this region is lower than the frequency of those directed against epitope Bi and epitope B2 (ratio of hybridomas recognizing Bi, B2, and B3 was 1.3:1.5:1) (data not shown).
Epitopes Bi and B2 were also recognized by day 14 antisera from Fischer rats seeded with primary BRK cells transfected with the plasmid pJ5f16E7 and an activated ras oncogene (Fig. 7) . ELISA results for antisera taken from rats 14 days postimmunization showed that the level of rat anti-E7 antibody was much lower than in mice immunized with fusion protein. This was likely to be due to the length of time between seeding and bleeding and to the level of E7 antigen to which the animals were exposed. Because of the vigorous growth of the tumors, further antiserum samples were not available.
Epitope predictions based on analysis of HPV16 E7 protein secondary structure. Computer traces for the algorithms used in the secondary-structure prediction of HPV16 E7 are shown in Fig. 2 with numbers representing the amino acid residues of HPV16 E7 (residue number 1 corresponds to methionine).
Epitopes B2 and B3 were predicted by the WKS, WJA NIN, WHPLC, and WFPPI algorithms, indicating high chain flexibility, high accessibility, and a high degree of hydrophilicity. The overall pattern suggests the strong likelihood of two distinct epitopes in the region covering epitope B2 because of peak increases at either end of this long region (overall, residues 35 to 54). Only the C-terminal half of epitope B1 is predicted by these algorithms. The T epitope Ti is strongly predicted by the PRIFTA and FPPIA algorithms, with residues 23 to 30 being most strongly represented, and a CORE trough at residues 20 to 22. The algorithm described by DeLisi and Berzofsky (8) predicts part of this region (residues 26 to 32) as a potential T-cell epitope. Epitope T4 is also represented by high PRIFTA and FPPIA traces and by two CORE troughs. Only residues in epitope T4 (GTLG) and the first two residues of epitope Ti (TD) are included in T-cell epitopes predicted by the motif of Rothbard and Taylor (45) .
DISCUSSION
The aim of this investigation was to identify and characterize murine T-and B-cell epitopes of the major transforming gene of HPV16. To this end, we have identified four T-cell epitopes (Ti to T4) and three B-cell epitopes (Bi to B3) (Fig. 8) within the E7 protein by analysis of antisera from E7-immunized BALB/c, B10.S, and CBA mice and proliferative T-cell responses from E7-fusion protein-immunized CBA mice. A nested set of overlapping peptides spanning the entire HPV16 E7 sequence was used. The lymphoproliferative assay used here predominantly measures the proliferation of T helper cells. However, as no further analysis was carried out, we cannot say with certainty that the T-cell determinants identified were specifically T-helper-cell epitopes.
Epitope B3 is a previously unreported epitope and was identified by analysis of antisera from CBA mice seeded with L cells transfected with HPV16 E7 and by preliminary analysis of hybridoma supernatants generated by immunization of CBA mice with two E7 fusion proteins (data not shown). In addition, antisera from Fischer rats seeded with BRK cells immortalized by cooperative transformation by HPV16 E7 and ras also recognized the murine epitopes Bi and B2.
Although an effective antibody response against infection with HPV (perhaps directed towards the viral capsid proteins Li and L2) may be important in the early stages of infection, it is likely that a functional T-cell response against other viral antigens is indispensable for the ultimate control of disease. The recognition of T-cell determinants by T cells (particularly T The four HPV16 E7 T-cell determinants identified were uniformly distributed over the entire protein, while the humoral response was predominantly directed towards the N-terminal half of the protein. In addition, it was observed that T-cell epitope T2 and B-cell epitope B2 overlapped. Peptides covering this region (939 and 940) consistently produced the highest level of T-cell stimulation as well as the strongest response in ELISAs, suggesting that this region may be particularly immunodominant in terms of both Band T-cell recognition. Indeed, ELISA results with antisera raised against the E7-fusion protein in all three strains of mice showed that almost all of the response mounted against the fusion protein was mounted against epitope B2. The observed immunodominance of this region of the E7 protein may reflect the fact that Tindle et al. (58) , using smaller peptides, have identified two distinct epitopes (IDGP and QAEPD) within our epitope B2. In this report, the fine definition of two epitopes within epitope B2 was not possible because of the longer peptides used.
Epitopes B3 and T3 also overlapped. This observed commonality of B-and T-cell epitopes is not transformed by HPV16E7 and ras is significant, as these epitopes may represent particularly immunodominant regions common to different species. Indeed, a recent study reported by Krchnak et al. (28) has shown that the human B-cell response to HPV16 E7 in patients with cervical intraepithelial neoplasia and invasive carcinoma is almost completely directed towards the N-terminal half of the protein and in particular towards amino acids within residues 10 to 30 and 40 to 60. The results presented in this paper for the murine models are in agreement with the human data, with the major murine B-cell epitope occurring between residues 35 and 49 and a second epitope occurring between residues 10 and 20. (17, 24) . It is difficult to say whether this figure truly represents the number of HPV-positive individuals possessing anti-E7 antibodies, as this low percentage may be indicative of a particular stage of infection or disease when the sera were taken.
We undertook the preliminary analysis of a panel of serum samples from women with abnormal cervical-smear results and found that 3 of the 19 samples tested were positive by ELISA for anti-E7 antibodies against the GST16E7 fusion protein. These three serum samples were then assayed against E7 peptides and fusion protein once more. Two of the samples recognized the murine-rat epitope B2, two recognized epitope B3, and 1 recognized epitope B1, with no one sample recognizing all three epitopes (data not shown). The HPV statuses of these patients were unknown at the time of assay, and further patient information and analysis of a much larger number of patient serum samples will be needed before a pattern of human E7 B-cell epitope recognition begins to emerge. Krchnak et al. (28) have postulated that epitope B2 is a type-common epitope, as evidenced by high reactivities to this region with sera from HPV6/11-and HPV18-positive patients, even though the amino acid homology between different HPV types in this region is low.
The analysis of human T-cell responses to HPV16 E7 may be possible through the availability of peripheral blood lymphocytes from infected individuals, which may be stimulated with E7 fusion proteins or peptides. Strang 
